Publications and Presentations

Effects of NSI-189, a neurogenic compound, on quantitative electroencephalography (qEEG) in patients with major depressive disorder (MDD) during a phase 1b randomized, double-blind, placebo controlled, multiple ascending dose study

Authors: Brett English, PharmD, PhD, Jack Johnstone, PhD, Karl Johe, PhD, Lev Gertsik, MD, Molly Sherman, Maurizio Fava, MD Larry Ereshefsky, PharmD

The International College of Neuropsychopharmacology (CINP), Abstract posted June 17, 2014, in advance of presentation at 29th CINP World Congress of Neuropsychopharmacology: June 24, 2014.

A Phase 1B, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Escalation Study Evaluating the Effects of NSI-189 Phosphate, a Neurogenic Compound, in Patients with Major Depressive Disorder (MDD)

Authors: Maurizio Fava, MD, Karl Johe, PhD, Lev G. Gertsik, MD, Larry Ereshefsky PharmD, Bettina Hoeppner, PhD, Martina Flynn, David Mischoulon, MD, PhD, Gustavo Kinrys, MD, and Marlene Freeman, MD

American Society of Clinical Psychopharmacology (formerly NCDEU), Abstract posted May 23, 2014, in advance of oral presentation at ASCP Annual Meeting: June 17, 2014.